Evidence map›Paper›PMID 38977356›Full record

ArticleLupus science & medicine2024

Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus-formation analysis system (T-TAS).

Daisuke Hiraoka, Jun Ishizaki, Jun Yamanouchi, Takatsugu Honda, Toshiyuki Niiya, Erika Horimoto, Kenta Horie, Hitoshi Yamasaki, Takuya Matsumoto, Koichiro Suemori and 2 more

Abstract read
In one paragraph

Article in Lupus science & medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Lupus Nephritis from Pathogenesis to New Therapies: An Update.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Daisuke HiraokaDepartment of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Japan.ORCID 0000-0003-3645-3872
Jun IshizakiDepartment of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Japan ishizaki@m.ehime-u.ac.jp.
Jun YamanouchiDepartment of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Japan.
Takatsugu HondaClinical Laboratory Department, Ehime University Hospital, Toon, Japan.
Toshiyuki NiiyaClinical Laboratory Department, Ehime University Hospital, Toon, Japan.
Erika HorimotoDepartment of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Japan.
Kenta HorieDepartment of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Japan.
Hitoshi YamasakiInternal medicine, Saiseikai Imabari Hospital, Imabari, Japan.
Takuya MatsumotoDepartment of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Japan.
Koichiro SuemoriDepartment of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Japan.
Hitoshi HasegawaRheumatic Center, Ozu Memorial Hospital, Ozu, Japan.
Katsuto TakenakaDepartment of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesHydroxychloroquine (HCQ) has been shown to reduce thrombotic events in patients with SLE. However, the antiplatelet effects of HCQ are only supported by the platelet aggregation assay, which is a non-physiological test. The total thrombus-formation analysis system (T-TAS) is a microchip-based flow chamber system that mimics physiological conditions and allows for the quantitative analysis of thrombogenicity. The present study investigated the antiplatelet effects of HCQ using T-TAS.

methodsThis was a single-centre cross-sectional study on 57 patients with SLE. We measured the area under the pressure curve for 10 min (PL-AUC

resultsPL-AUC

conclusionsWe demonstrated the antiplatelet effects of HCQ under conditions simulating the physiological environment by using T-TAS and identified the range of doses at which HCQ exerted antiplatelet effects.

Indexed as

HydroxychloroquineLupus Erythematosus, SystemicPlatelet AggregationPlatelet Aggregation InhibitorsThrombosisAdultAntirheumatic AgentsCross-Sectional StudiesFemaleHumansMaleMiddle AgedPlatelet Function TestsYoung AdultAntirheumatic AgentsHydroxychloroquinePlatelet Aggregation InhibitorsCardiovascular DiseasesLupus Erythematosus, SystemicMyocardial infarction

Identifiers

PMID38977356
PMCPMC11256038

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.